Journal
CELL
Volume 156, Issue 4, Pages 633-648Publisher
CELL PRESS
DOI: 10.1016/j.cell.2014.01.052
Keywords
-
Categories
Funding
- Collaboration for AIDS Vaccine Discovery (CAVD) grant from the Bill and Melinda Gates Foundation [1040753]
- National Institutes of Health [HIVRAD P01 AI100148, DP1OD006961]
- NIH Center for HIV/AID Vaccine Immunology and Immunogen Discovery (CHAVI-ID) [1UM1 AI100663-01]
- American Cancer Society [PF-13-076-01-MPC]
- Stavros Niarchos Foundation
Ask authors/readers for more resources
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent HIV-1 infection in humanized mice and macaques when passively transferred. New single-cell-based methods have uncovered many broad and potent donor-derived antibodies, and structural studies have revealed the molecular bases for their activities. The new data suggest why such antibodies are difficult to elicit and inform HIV-1 vaccine development efforts. In addition to protecting against infection, the newly identified antibodies can suppress active infections in mice and macaques, suggesting they could be valuable additions to anti-HIV-1 therapies and to strategies to eradicate HIV-1 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available